Clinical trial
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for…
NCT00074048 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00074048 |
|---|---|
| Title | BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia |
| Official title | Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | BL22 |
| Enrollment | 36 |
| Start date | Oct 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Dec 11, 2003 |
| Last update posted | Jun 22, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: